Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) and HCW Biologics (NASDAQ:HCWB – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.
Institutional & Insider Ownership
82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Inhibrx Biosciences and HCW Biologics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibrx Biosciences | 1 | 2 | 2 | 1 | 2.50 |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
Profitability
This table compares Inhibrx Biosciences and HCW Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibrx Biosciences | N/A | -563.90% | -83.48% |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
Earnings & Valuation
This table compares Inhibrx Biosciences and HCW Biologics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibrx Biosciences | $1.30 million | 1,244.86 | -$140.05 million | ($8.88) | -12.38 |
| HCW Biologics | $50,000.00 | 89.17 | -$7.96 million | ($27.60) | -0.09 |
HCW Biologics has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Inhibrx Biosciences has a beta of 3.66, indicating that its share price is 266% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500.
Summary
Inhibrx Biosciences beats HCW Biologics on 10 of the 15 factors compared between the two stocks.
About Inhibrx Biosciences
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
